Early Treatment of ARNI on Myocardial Remodeling and Progress

• Status: Not yet recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Myocardial remodeling following myocardial infarction (MI) is an important prognostic factor for heart function and adverse cardiovascular events, especially are intimately linked with heart failure. MI often causes deleterious changes in ventricular size, shape, and function. This adverse remodeling and progress is mediated by neurohormonal and hemodynamic alterations. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was shown to be superior to an ACE inhibitor in patients with heart failure with reduced ejection fraction (HF-REF), reduce the risk of both death (from cardiovascular and all-causes) and heart failure hospitalization, may be a new approach to the treatment of heart failure. However, the impact of early treatment of ARNI on myocardial remodeling and progress, and aerobic exercise capacity in patients with prior MI has yet to be assessed. The aim of this study is to evaluate the efficacy and the safety of early treatment of ARNI on myocardial remodeling and progress, and aerobic exercise capacity in patients following MI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Treatments: LCZ 696; Perindopril; Valsartan

Criteria

Inclusion Criteria:

1. Acute myocardial infarction (AMI) within 1 months prior to recruitment;

2. Aged 18 years or over and under 80 years;

3. Randomized patients will have been hemodynamically stable, SBP ≥100mmHg, no symptomatic hypotension;

4. NYHA Class Ⅱ-Ⅳ, HFrEF or HFpEF;

5. Elevated NT-proBNP or BNP at the time of screening;

6. Peak VO2/kg<16 ml/kg/min by CPET

Exclusion Criteria:

1. Inability to complete a CPET;

2. Symptomatic hypotension and/or systolic blood pressure <100mmHg;

3. eGFR < 30 mL/min/1.73m2 and/or serum potassium >5.2mmol/L;

4. History of hypersensitivity or allergy to ACE-inhibitors/ARB

5. History of angioedema;

6. Pregnancy, planning pregnancy, or breast feeding;

7. Life-threatening diseases with limited life expectancy <1 year